Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

relapsed chronic lymphocytic leukaemia

J&J files intravenous Simponi formulation in US

FDA approval would complement J&J’s current subcutaneously-administered product

China flag thumb

China slashes drug prices as healthcare reforms announced

Raft of measures to cut healthcare costs include 17 per cent price reduction for cancer drugs

Cornerstone slumps as FDA panel votes down lead pipeline drug

US pharma company asked to conduct new trials for its hyponatremia treatment

- PMLiVE

FDA urged to give biosimilar medicines distinct scientific names

Alliance for Safe Biologic Medicines highlights safety concerns if different products have same name

- PMLiVE

Sanofi taps Oncodesign for kinase inhibitor platform

French firms form €130m alliance

- PMLiVE

Finalists decided in UK cancer awards

QiC Excellence in Oncology aims to recognise good practice in cancer care throughout UK

- PMLiVE

FDA clears Sanofi’s oral MS drug Aubagio

Will compete with Novartis’ Gilenya

- PMLiVE

J&J responds to FDA concerns over Xarelto in ACS

Responds to regulator about missing clinical trial data

- PMLiVE

Merck KGaA acquires cancer drug from Symphogen

Will pay up to €495m for investigational metastatic colorectal cancer treatment

FDA sued for approving high dose of Eisai’s Alzheimer’s drug Aricept

Consumer rights group Public Citizen claims the high-strength dose is unsafe

Roche - Basel

Roche says pipeline will balance cancer drug patent losses

Has 11 new molecular entities in late-stage portfolio and 11 line extensions

Novartis building

FDA panel backs Novartis’ updated cystic fibrosis drug

New version of inhaled tobramycin therapy is simpler to use

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links